Decreased intestinal CYP3A in celiac disease: Reversal after successful gluten-free diet: A potential source of interindividual variability in first-pass drug metabolism

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 1, 1996, Pages 41-46

  Lang, Chim C ^b   Brown, R Michael ^b   Kinirons, Mark T ^b   Deathridge, Mary Ann ^b   Guengerich, F Peter ^b   Kelleher, Dermot ^b   O'Briain, D Sean ^b   Ghishan, Fayez K ^b   Wood, Alastair J J ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; CYTOCHROME P450; DAPSONE; ERYTHROMYCIN; MIDAZOLAM; QUINIDINE; TAMOXIFEN; TRIAZOLAM;

ADULT; ARTICLE; BIOPSY; CELIAC DISEASE; CLINICAL ARTICLE; DRUG DISPOSITION; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GLUTEN FREE DIET; HUMAN; MALE; PRIORITY JOURNAL; SMALL INTESTINE;

ADULT; BIOPSY; CELIAC DISEASE; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GLUTEN; HUMANS; IMMUNOENZYME TECHNIQUES; INTESTINE, SMALL; MALE; MIXED FUNCTION OXYGENASES; REPRODUCIBILITY OF RESULTS;

EID: 0030053064     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90022-3     Document Type: Article

References (25)

1. Bonkovsky HL, Hauri HP, Marti U, Gasser R, Meyer UA. Cytochrome P450 of small intestinal epithelial cells: immunochemical characterization of the increase in cytochrome P450 caused by phenobarbital. Gastroenterology 1985;88:458-67.
2. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extra hepatic tissues. J Pharmacol Exp Ther 1990;253:387-94.
3. Traber PG, Chianale J, Florence R, Kim K, Wojcik E, Gumucio JJ. Expression of cytochrome P450b and P450e genes in small intestinal mucosa of rats following treatment with phenobarbital, polyhalogenated diphenyls and organochlorine pesticides. J Biol Chem 1988;263:9449-55.
4. Kolars JC, Schmiedlin-Ren P, Dobbins WO III, Schuetz J, Wrighton SA, Watkins PB. Heterogeneity of cytochrome P-450 III expression in rat gut epithelia. Gastroenterology 1992;102:1186-98.
5. Rich KJ, Sesardic D, Foster JR, Davies DS, Boobis AR. Immunohistochemical localization of cytochrome P450 b/e in hepatic and extrahepatic tissues of the rat. Biochem Pharmacol 1989;38:3305-22.
6. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochrome P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987;80:1029-36.
7. Murray GI, Barnes TS, Sewell HF, Ewen SW, Melvin WT, Burke MD. The immunochemical localization and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with monoclonal antibody to human cytochrome P-450. Br J Clin Pharmacol 1988;25:465-75.
8. Watkins PB. Drug metabolism by cytochrome P450 in the liver and small bowel. Gastroenterol Clin North Am 1992;21:511-26.
9. NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc Natl Acad Sci USA 1989;86:462-5.
10. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano, ed. Cytochrome P450. New York: Plenum Press, 1995:473-535.
11. Kronbach T, Fischer V, Meyer U. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine metabolizing enzyme explains interactions of cyclosporine with other drugs. CLIN PHARMACOL THER 1988;43:630-5.
12. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation: a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986;261:5051-60.
13. Ferguson A, Arranz E, O'Mahony S. Clinical and pathological spectrum of coeliac disease - active, silent, latent, potential. Gut 1993;24:150-1.
14. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
15. Krishna DR, Klotz U. Extra hepatic metabolism of drugs in humans. Clin Pharmacokinet 1994;26:144-60.
16. Ilett KF, Tee LBG, Reeves PT, Minchin RF. Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol Ther 1990;46:67-93.
17. Kolars JC, Stetson PL, Rush BD, et al. Cyclosporin metabolism by P450IIIA in rat enterocytes - another determinant of oral bioavailability? Transplantation 1992;53:596-602.
18. Kolars JC, Awai WM, Merion RM, Watkins PB. First pass metabolism of cyclosporin by the gut. Lancet 1991;338:1488-90.
19. Ames BN. Mutagenesis and carcinogenesis: endogenous and exogenous factors. Environ Mol Mutagen 1989;16:S66-7.
20. Felton JS, Knize MG. Occurrence, identification, and bacterial mutagenicity of heterocyclic amines in cooked food. Mutat Res 1991;259:205-17.
21. Willett WC, Stampfer GA, Colditz BA, Rosner BA, Speizer FE. Relation of meat, fat, and fiber to the risk of colon cancer in a prospective study among women. N Engl J Med 1990;323:1664-72.
22. Buonarati MH, Turtelaub KW, Felton JS. Role of sulfation and acetylation in the activation of 2-hydroxyamino-1-methyl-6-phenlimidazo[4,5-b]pyridine (PHIP) to intermediates which bind to DNA. Mutat Res 1990;245:185-90.
23. Turesky RJ, Long NP, Butler MA, Teitel CH, Kadlubar FF. Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis 1991;12:1839-45.
24. Hoensch HP, Hartmann F. The intestinal enzymatic biotransformation system: potential role in protection from colon cancer. Hepatogastroenterology 1981;28:221-8.
25. Swinson CM, Slavin G, Coles EC, Booth CC. Coeliac disease and malignancy. Lancet 1983;1:111-5.